Wedbush reissued their outperform rating on shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) in a research report report published on Wednesday morning. Wedbush currently has a $28.00 price objective on the stock.
Several other analysts have also commented on CLSD. Zacks Investment Research raised shares of Clearside Biomedical from a sell rating to a hold rating in a research report on Tuesday, October 11th. Stifel Nicolaus lifted their price target on shares of Clearside Biomedical from $13.00 to $23.00 and gave the company a buy rating in a research report on Monday, October 24th. Finally, Needham & Company LLC lifted their price target on shares of Clearside Biomedical from $16.00 to $24.00 and gave the company a buy rating in a research report on Thursday, November 10th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Clearside Biomedical currently has an average rating of Buy and a consensus price target of $24.25.
Shares of Clearside Biomedical (NASDAQ:CLSD) opened at 7.71 on Wednesday. Clearside Biomedical has a 12 month low of $5.65 and a 12 month high of $25.08. The firm’s 50-day moving average price is $8.43 and its 200 day moving average price is $12.26. The company’s market cap is $158.58 million.
TRADEMARK VIOLATION WARNING: This story was posted by sleekmoney and is the sole property of of sleekmoney. If you are accessing this story on another domain, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be read at http://sleekmoney.com/clearside-biomedicals-clsd-outperform-rating-reiterated-at-wedbush/1657483.html.
In other Clearside Biomedical news, insider Venture Advisors Iii Hatteras sold 25,301 shares of the business’s stock in a transaction that occurred on Thursday, January 19th. The stock was sold at an average price of $8.63, for a total value of $218,347.63. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Clay Thorp sold 68,485 shares of the business’s stock in a transaction that occurred on Friday, January 20th. The shares were sold at an average price of $8.53, for a total value of $584,177.05. The disclosure for this sale can be found here.
Several hedge funds have recently bought and sold shares of CLSD. FMR LLC raised its stake in Clearside Biomedical by 377.3% in the fourth quarter. FMR LLC now owns 1,029,600 shares of the company’s stock worth $9,205,000 after buying an additional 813,889 shares in the last quarter. Hillhouse Capital Management Ltd. bought a new stake in Clearside Biomedical during the third quarter worth $10,410,000. Marshall Wace LLP raised its stake in Clearside Biomedical by 181.1% in the fourth quarter. Marshall Wace LLP now owns 449,820 shares of the company’s stock worth $4,021,000 after buying an additional 289,820 shares in the last quarter. Iguana Healthcare Management LLC bought a new stake in Clearside Biomedical during the second quarter worth $526,000. Finally, State Street Corp raised its stake in Clearside Biomedical by 80.7% in the fourth quarter. State Street Corp now owns 102,278 shares of the company’s stock worth $911,000 after buying an additional 45,671 shares in the last quarter. 33.52% of the stock is currently owned by institutional investors and hedge funds.
About Clearside Biomedical
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/clearside-biomedicals-clsd-outperform-rating-reiterated-at-wedbush/1657483.html
Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.